Cure S - Search Results

1

Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C.

Pfeil AM, Reich O, Guerra IM, Cure S, Negro F, Müllhaupt B, Lavanchy D, Schwenkglenks M. Pfeil AM, et al. Among authors: cure s. PLoS One. 2015 May 14;10(5):e0126984. doi: 10.1371/journal.pone.0126984. eCollection 2015. PLoS One. 2015. PMID: 25974722 Free PMC article.

2

Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients.

Cure S, Guerra I, Dusheiko G. Cure S, et al. J Viral Hepat. 2015 Nov;22(11):882-9. doi: 10.1111/jvh.12409. Epub 2015 Apr 7. J Viral Hepat. 2015. PMID: 25847572

3

Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy.

Cure S, Guerra I, Cammà C, Craxì A, Carosi G. Cure S, et al. J Med Econ. 2015;18(9):678-90. doi: 10.3111/13696998.2015.1040024. Epub 2015 Jun 5. J Med Econ. 2015. PMID: 25891129 Free article.

4

Cost-Effectiveness and Long-Term Outcomes of Sovaldi (SOFOSBUVIR) for the Treatment of Chronic Hepatitis C Infected (HCV) Patients from a Swedish Societal Perspective.

Cure S, Guerra I. Cure S, et al. Value Health. 2014 Nov;17(7):A675. doi: 10.1016/j.jval.2014.08.2508. Epub 2014 Oct 26. Value Health. 2014. PMID: 27202487 Free article. No abstract available.

5

Cost-utility analysis of sofosbuvir for the treatment of genotype 2 chronic hepatitis C in Japan.

Igarashi A, Tang W, Cure S, Guerra I, Marié L, Lopresti M, Tsutani K. Igarashi A, et al. Among authors: cure s. Curr Med Res Opin. 2017 Jan;33(1):1-10. doi: 10.1080/03007995.2016.1222512. Epub 2016 Sep 8. Curr Med Res Opin. 2017. PMID: 27608157

6

Cost-utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan.

Igarashi A, Tang W, Guerra I, Marié L, Cure S, Lopresti M. Igarashi A, et al. Among authors: cure s. Curr Med Res Opin. 2017 Jan;33(1):11-21. doi: 10.1080/03007995.2016.1222513. Epub 2016 Sep 9. Curr Med Res Opin. 2017. PMID: 27609424

7

Long-Term Outcomes of Ledipasvir/Sofosbuvir (LDV/ SOF) for the Treatment of Chronic Hepatitis C Infected (HCV) Genotype 1 Patients in the UK.

Guerra I, Marie L, Cure S. Guerra I, et al. Among authors: cure s. Value Health. 2014 Nov;17(7):A675. doi: 10.1016/j.jval.2014.08.2507. Epub 2014 Oct 26. Value Health. 2014. PMID: 27202486 Free article. No abstract available.

8

Cost-Utility Analysis Of Sofosbuvir For Treatment Of Genotype2 Chronic Hepatitis C In Japan.

Igarashi A, Tang W, Cure S, Guerra I, Lopresti M, Tsutani K. Igarashi A, et al. Among authors: cure s. Value Health. 2014 Nov;17(7):A368. doi: 10.1016/j.jval.2014.08.827. Epub 2014 Oct 26. Value Health. 2014. PMID: 27200774 Free article. No abstract available.

9

Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients.

Cure S, Bianic F, Gavart S, Curtis S, Lee S, Dusheiko G. Cure S, et al. J Med Econ. 2014 Jan;17(1):77-87. doi: 10.3111/13696998.2013.844159. Epub 2013 Nov 21. J Med Econ. 2014. PMID: 24032626 Free article.

10

Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients.

Cure S, Bianic F, Gavart S, Curtis S, Lee S, Dusheiko G. Cure S, et al. J Med Econ. 2014 Jan;17(1):65-76. doi: 10.3111/13696998.2013.860033. Epub 2013 Nov 18. J Med Econ. 2014. PMID: 24160335 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

49 results

Search Page

Filters